Entries by

Newcomers entering the anti-obesity market bring optimism, but face tough challenges

Favourable market conditions. The anti-obesity market is predicted to be worth $2.4 billion by 2021, growing 21% annually. High unmet need and advantageous epidemiological trends are key drivers. At first glance, the opportunity for new therapies seems considerable. Limited success for Pharma so far. For decades drug developers have had limited success in grabbing this […]

A time for giving: Christmas 2012

This Christmas, as in previous years, we have made donations to our chosen charities. We are supporting the UK charity Action MS.  Action MS maintains a highly successful fund-raising programme that supports research into multiple sclerosis, and an extensive range of care and support services to people and families living with MS. In addition, this […]

One way we are aiming to create shared value

Each year, at Christmas time, we donate a proportion of our operating profit to our two chosen charities. The decision to support charities was taken at the very outset of the formation of groupH.  It’s simply something that we feel is the right thing to do, not just something to put in our Corporate Social […]

Eugene Tierney, former Head of Central Nervous System at Roche

We were very privileged to speak to Eugene Tierney, formerly head of CNS at Roche, in September 2012 at Somerset House in central London. Somerset House seemed to be a more than fitting location for this conversation – a neo-classical building dating back to the 15th century, it sits between the Strand and the River […]